Report overview
This report contains market size and forecasts of Squamous Non-Small Cell Lung Cancer Therapeutics in Global, including the following market information:
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Squamous Non-Small Cell Lung Cancer Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
BMS-906024 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Squamous Non-Small Cell Lung Cancer Therapeutics include Ascenta Therapeutics, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Bayer AG, BIND Therapeutics, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company and F. Hoffmann-La Roche Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Squamous Non-Small Cell Lung Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Percentages, by Type, 2021 (%)
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Percentages, by Application, 2021 (%)
Research Center
Hospital
Clinic
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Squamous Non-Small Cell Lung Cancer Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Squamous Non-Small Cell Lung Cancer Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
